https://orcid.org/0000-0003-2289-1521
References
- Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
- Riihimaki M , HemminkiA, SundquistJ, HemminkiK. Patterns of metastasis in colon and rectal cancer. Sci. Rep.6, 29765 (2016).
- Lakatos G , KöhneCH, BodokyG. Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. Cancer Metastasis Rev.39(4), 1143–1157 (2020).
- European Medicines Agency. Merck . Summary of product characteristics, Erbitux. (2022). www.ema.europa.eu/en/medicines/human/EPAR/erbitux
- US Food and Drug Administration . Erbitux. Prescribing Information. EMD Serono, Inc., USA (2021). www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s277s280lbl.pdf
- Van Cutsem E , LenzHJ, KöhneCHet al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol.33(7), 692–700 (2015).
- Bokemeyer C , KöhneCH, CiardielloFet al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur. J. Cancer51(10), 1243–1252 (2015).
- Qin S , LiJ, WangLet al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J. Clin. Oncol.36(30), 3031–3039 (2018).
- Cheng A-L , CornelioG, ShenLet al. Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase II APEC study. Clin. Colorectal Cancer16(2), e73–e88 (2017).
- Bokemeyer C , BondarenkoI, HartmannJTet al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol.22(7), 1535–1546 (2011).
- Price T , ShenL, MaBet al. Phase II APEC trial: the impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. Asia Pac. J. Clin. Oncol.15(4), 225–230 (2019).
- Cremolini C , BenelliM, FontanaEet al. Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open4(2), e000489 (2019).
- Loree JM , PereiraAAL, LamMet al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin. Cancer Res.24(5), 1062–1072 (2018).
- Sunakawa Y , TsujiA, FujiiM, IchikawaW. No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?Ann. Oncol.28(8), 2030–2031 (2017).